Cytophage Technologies Concludes Private Placement, Raises $1.2 Million

WINNIPEG, Manitoba — November 28, 2025 — Leads & Copy — Cytophage Technologies Ltd. has closed the remaining portion of its non-brokered private placement, raising an additional $198,000 in gross proceeds.

The closing, announced today, involved issuing 990,000 units to investors, bringing the total gross proceeds from the offering to $1,200,000. The initial details of the offering were disclosed in a press release on October 17, 2025.

Each unit, priced at $0.20, includes one common share of Cytophage and one-half of a common share purchase warrant. A whole warrant allows the holder to purchase one additional share at C$0.40 per share for 24 months from the issuance date.

Cytophage retains the right to accelerate the warrants' expiry if the volume-weighted average trading price of its common shares on the TSX Venture Exchange reaches or exceeds $0.60 for 10 consecutive trading days. The company will notify all warrant holders if it exercises this acceleration right.

The company has also agreed to pay finder’s fees of $4,200 in cash and issue 21,000 broker warrants, under the same terms as the warrants from the offering, to qualified non-related parties, pending Exchange approval.

All securities issued in connection with the closing are subject to a four-month hold period, in accordance with the Exchange's rules, policies and applicable Canadian securities laws.

Cytophage plans to use the net proceeds to advance its phage technology in human health, animal health, and food security, as well as for general corporate purposes. The closing of the offering is still subject to regulatory approvals from the TSX Venture Exchange.

The securities offered have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold in the United States without registration or an applicable exemption. The release does not constitute an offer to sell or the solicitation of an offer to buy securities in any jurisdiction where such an offer, solicitation, or sale would be unlawful.

Cytophage Technologies has also released its financial results for the third quarter (Q3) ended September 30, 2025. The quarterly financial statements and management discussion are available on SEDAR+.

Cytophage Technologies (TSXV:CYTO / FSE: 70G) focuses on bacteriophage research, product development, and commercialization. Bacteriophages are viruses that exclusively infect and kill bacteria, offering a natural alternative to antibiotics.

The company aims to improve these natural bacteria killers through environmental and genetic modifications, creating safe and toxin-free solutions for markets, initially targeting animal health for near-term revenue. Cytophage, a bacteriophage manufacturer in Canada, is addressing the global challenge of antibiotic resistance, as the WHO projects it to be the leading cause of human mortality by 2050.

Cytophage utilizes patented technology to develop innovative and cost-competitive products that use bacteriophages to combat bacterial infections in human health, animal health, and food security.

For further information, contact Julius Kalcevich, Chief Financial Officer, at julius.kalcevich@cytophage.com or 647 705 5544.

Cytophage Investor Alerts: https://cytophage.com/subscribe/

Source: Cytophage Technologies Ltd.

Source: Cytophage Technologies Ltd.